DJIA 17,042.90 -28.32 -0.17%
NASDAQ 4,493.39 -12.46 -0.28%
S&P 500 1,972.29 -5.51 -0.28%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

117.43 -3.11 (-2.58%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PCYC $117.43 -2.58%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $120.98
Previous Close $120.54
Daily Range $117.42 - $121.09
52-Week Range $82.51 - $154.89
Market Cap $8.8B
P/E Ratio 103.03
Dividend (Yield) $0.00 (0.0%)
Volume 758,328
Average Daily Volume 789,246
Current FY EPS $0.25

Sector

Healthcare

Industry

Drugs

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary Rss Feed

Gilead Sciences, Inc. Stock's Stunning New Opportunity

The biotech giant has spent over $1.2 billion to buy blood cancer drugs. And with Zydelig's recent approval, it looks like it's finally struck gold.

FDA Decision On Imbruvica Will Push Pharmacyclics Higher

Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

Cramer's Lightning Round - People Need H&R Block More Than Ever (9/17/14)

UPDATE: Morgan Stanley Reiterates On Pharmacyclics, Inc. Following VA Contract News

Trade-Ideas: Pharmacyclics (PCYC) Is Today's "Barbarian At The Gate" Stock

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News

Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News

Infinity Pharma Snags Abbvie for Blood Cancer Drug Partnership

Target Expected To Be Right On Target With Earnings

See More PCYC News...

PCYC's Top Competitors

PCYC $117.43 (-2.58%)
Current stock: PCYC
GILD $106.45 (-0.99%)
Current stock: GILD
CELG $94.78 (-0.90%)
Current stock: CELG
BIIB $330.81 (0.20%)
Current stock: BIIB